Molina Q3 EPS $0.73, Revenue Declines; Key Metrics Still Pending

What happened

Molina Healthcare reported Q3 2026 GAAP EPS of $0.73 and adjusted EPS of $0.89, down from $1.19 GAAP EPS in the prior quarter. Premium revenue declined 3.5% year-over-year to $10.457 billion, with total revenue down 3.4% to $11.082 billion, reflecting the ongoing deliberate reduction in Marketplace footprint and lower Medicaid enrollment. The press release does not disclose medical care ratio by segment, so it is unclear whether Marketplace MCR improved from the 88.9% reported in Q2, a key thesis checkpoint. Nine-month premium revenue of $30.873 billion is down 4.5% from $32.337 billion in 2025, and adjusted EPS of $0.89 remains depressed relative to historical norms. The company is approaching the Q4 2026 Florida Medicaid launch and 2027 Marketplace repricing, which will be critical to validating the earnings recovery thesis.

Implication

The Q3 results show revenue contraction but do not provide enough detail to confirm or refute the thesis that Marketplace MCR is improving and Florida will launch on time. Without MCR data, the market may interpret the lower EPS and revenue as continuation of the ACA cleanup story, potentially pressuring the stock further. However, the adjusted EPS of $0.89 is not a disaster: it still represents positive earnings, and the company has a strong cash position and Medicaid stability. The key upcoming catalysts are the Q4 earnings release (which will include Florida start-up costs) and the final 2027 ACA pricing, both of which will determine if the bear case or bull case prevails. Given the unchanged uncertainty, the WAIT rating remains appropriate, with an attractive entry near $175 and a trim above $235, but investors should monitor for any signs of MCR improvement or Florida execution slippage.

Thesis delta

The Q3 results do not materially change the thesis because the critical metrics (Marketplace MCR and Florida launch status) are not yet disclosed. The sequential decline in EPS and revenue adds a slight negative tilt, reinforcing the risk that Marketplace losses persist. However, the core Medicaid franchise remains stable, and the upcoming Q4 report will be the decisive test for the earnings recovery hypothesis.